{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tarlatamab"]],"indication":null,"name":"DeLLphi-307","nct_id":"NCT06502977","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-307-nct06502977. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DeLLphi-307","arms":[{"description":"Participants will receive tarlatamab as an intravenous (IV) infusions in 28-day cycles.","label":"Tarlatamab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-10","type":"ESTIMATED"},"conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":{"count":32,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tarlatamab","otherNames":["AMG 757","IMDELLTRA™"],"type":"DRUG"}],"last_update":"2026-10-21","lead_sponsor":"Amgen","official_title":"Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-03-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off"}],"references":[],"start_date":{"date":"2024-08-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","url":"https://clinicaltrials.gov/study/NCT06502977"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-307-nct06502977"}